US President Donald Trump has unveiled a phased tariff plan for imported generic medicines that could reshape the global pharmaceutical industry and pose a major challenge for Indian drug manufacturers. Under the proposed policy, imported generic medicines will continue to enjoy zero tariffs from August 1, 2026, until July 31, 2028, after which they will face a 100% tariff for one year, followed by a 200% duty from August 1, 2029.

Announcing the policy on Truth Social, Trump said the move is aimed at encouraging pharmaceutical companies to relocate manufacturing facilities to the United States and reduce America's dependence on overseas drug production.

Two-Year Window to Shift Production

The phased approach gives global pharmaceutical companies a two-year transition period to establish manufacturing operations in the US before the higher tariffs take effect.

According to Trump, companies that invest in American production facilities during this period will be better positioned to avoid the steep import duties later. He described the initiative as part of a broader strategy to strengthen domestic pharmaceutical manufacturing and improve supply chain resilience.

The policy will apply only to generic medicines, while the administration's existing approach toward patented and innovative drugs will remain unchanged.

Major Implications for Indian Pharma

The announcement is being closely watched in India, which is one of the world's largest producers of generic medicines. India supplies nearly 30% of the world's generic drugs and is a key supplier to the US healthcare system.

Indian pharmaceutical companies derive a significant share of their revenue from the American market. If the proposed tariffs are implemented as announced, exporters may face difficult choices between absorbing higher costs, shifting manufacturing to the US, or passing additional expenses on to buyers.

Industry experts believe companies with existing manufacturing facilities in the United States may gain a competitive advantage, while firms relying entirely on exports from India could face increased financial pressure.

Supply Chains May Be Reshaped

Generic medicines are manufactured through highly integrated global supply chains involving active pharmaceutical ingredients (APIs), formulations, packaging, and logistics spread across multiple countries.

The proposed tariff roadmap is expected to prompt multinational pharmaceutical companies to reassess their production networks. Establishing manufacturing units in the US would require substantial investment and several years of planning, making the two-year transition period crucial for strategic decisions.

Analysts also warn that if production shifts cannot keep pace with demand, medicine prices in the US could increase despite the administration's broader efforts to reduce healthcare costs.

Wider Trade Strategy

The latest proposal builds on the Trump administration's broader protectionist trade agenda. Earlier this year, Washington introduced tariffs on several pharmaceutical imports while temporarily exempting generic medicines and biosimilars.

The new announcement extends that strategy to generic drugs, reflecting the administration's focus on boosting domestic manufacturing under national security and economic resilience objectives.

India Looks to Diversify Export Markets

Even as uncertainty grows over future access to the US market, Indian pharmaceutical exporters are expanding their presence in other regions.

The recently implemented India-UK Comprehensive Economic and Trade Agreement (CETA) is expected to improve market access for Indian medicines in the United Kingdom through zero-duty provisions and enhanced regulatory cooperation.

Industry bodies believe stronger exports to Europe and other international markets could partially offset any long-term impact if higher US tariffs eventually come into force.

Uncertainty Remains

While Trump has outlined the proposed timeline, industry stakeholders are awaiting detailed implementation guidelines from the White House and US trade authorities. Clarifications are expected regarding the treatment of different categories of generic medicines, pharmaceutical ingredients, and manufacturers with existing US operations.

For now, the announcement provides pharmaceutical companies with a clear timeline—but also a significant strategic challenge. The next two years are likely to determine how global drug manufacturers, particularly those in India, adapt to one of the most consequential changes in US pharmaceutical trade policy.

The United States and Canada are once again on the brink of a major trade confrontation after US President Donald Trump announced a sweeping 50% tariff on most Canadian goods entering the United States. The measure, set to take effect in 30 days, has opened a narrow window for negotiations but also revived concerns over inflation, supply chain disruptions, and renewed economic tensions between two of the world's closest trading partners.

The latest decision marks a significant escalation in trade relations between Washington and Ottawa. While the White House argues that the tariffs are necessary to counter what it describes as Canada's unfair treatment of American exports, Canadian leaders have warned that they are prepared to respond with reciprocal measures if negotiations fail.

Trump Targets Canadian Imports

President Trump invoked Section 338 of the Trade Act of 1930, a rarely used legal provision that grants the US president broad authority to impose tariffs on imports from countries deemed to be discriminating against American products.

Under the new order, most Canadian exports to the United States—including products that previously benefited from protections under the US-Mexico-Canada Agreement (USMCA)—will face a 50% tariff.

However, several strategic commodities have been exempted from the new levy. These include energy products, potash, fish, and critical minerals, reflecting their importance to American industries and supply chains.

According to the White House, the decision is aimed at addressing what it views as Canada's restrictive policies toward American automobiles, dairy products, and alcoholic beverages.

30-Day Negotiation Window

Although the tariffs have been announced, they will not come into force immediately. Instead, both governments have been given a 30-day period to negotiate a possible settlement and avoid a full-scale trade dispute.

The announcement provides diplomats and trade officials with one final opportunity to resolve longstanding disagreements before the tariffs begin affecting businesses and consumers.

Trade experts believe the next month will be crucial in determining whether the two countries can preserve the stability of one of the world's largest bilateral trading relationships.

Background of the Trade Dispute

The latest move is part of an ongoing cycle of retaliatory trade measures.

Last year, the Trump administration imposed tariffs on Canadian goods, citing concerns over border security and fentanyl trafficking. Canada responded by introducing 25% tariffs on selected American vehicles and suspending purchases of US alcoholic beverages across several provinces.

The White House now argues that Canada's retaliatory actions justify the latest tariff increase, while Canadian officials maintain that Ottawa was responding to earlier US restrictions.

Canada Signals Strong Response

Canadian leaders have strongly criticized Washington's latest decision while leaving the door open for negotiations.

Ontario Premier Doug Ford urged Ottawa to respond with equal force if the tariffs are implemented, saying Canada should answer "tariff for tariff, dollar for dollar."

Meanwhile, Candace Laing, President and CEO of the Canadian Chamber of Commerce, described the decision as disappointing but emphasized that both governments should use the next month to reach a negotiated agreement.

Canadian Prime Minister Mark Carney has also continued efforts to diversify Canada's trade partnerships with other global markets, reducing dependence on the United States.

Economic Impact Could Be Significant

Economists warn that higher import duties could ultimately be passed on to American consumers through increased prices for a wide range of products.

Since tariffs are paid by US importers rather than foreign exporters, businesses often offset the additional costs by raising retail prices. Industries dependent on cross-border supply chains—including manufacturing, automotive production, agriculture, and retail—could face higher operating costs if the tariffs take effect.

Analysts also caution that prolonged trade tensions could slow investment, disrupt North American supply chains, and place additional pressure on inflation at a time when businesses are already coping with rising costs.

With only 30 days remaining before implementation, negotiations between Washington and Ottawa are expected to intensify. Whether the two countries reach a compromise or enter another chapter of tariff battles will shape the future of North America's economic relationship.

The comments come amid ongoing negotiations between India and the United States aimed at resolving long-standing trade issues and strengthening economic cooperation.

Following a phone conversation between Trump and Modi in February, the two countries issued a joint statement outlining the framework for the first phase of a Bilateral Trade Agreement (BTA), also referred to as an interim trade deal.

Under that framework, the United States agreed in principle to lower tariffs on certain Indian goods from 50% to 18%.

Recent Negotiations in New Delhi

Trade officials from both countries held four days of discussions in New Delhi from June 1 to June 4. Representatives from the Office of the United States Trade Representative (USTR) met Indian officials to discuss:

• Trade in goods

• Customs procedures

• Trade facilitation measures

• Non-tariff barriers

• Economic security cooperation

Both sides described the talks as productive and said negotiations are continuing to finalise a mutually beneficial interim agreement.

Challenges Still Remain

Despite signs of progress, some uncertainty remains. The Trump administration is considering additional tariffs on imports from several economies, including India.

A proposed review under Section 301 of the US Trade Act of 1974 could lead to extra duties on imports from countries that the United States believes have not taken adequate measures against goods linked to forced labour.

India, along with China, Japan, South Korea, the United Kingdom, Bangladesh and Vietnam, is among the economies included in the review.

In a seismic shift for global trade, the US halts emergency tariffs imposed under the International Emergency Economic Powers Act (IEEPA). The US Customs and Border Protection (CBP) announced collections stop at 10:30 AM IST today, following a US Supreme Court verdict three days ago deeming them illegal.

This comes amid escalating trade tensions, making it highly relevant now as President Trump's aggressive policies reshape economies. Economists at Penn Wharton estimate a whopping $175 billion (₹15.75 lakh crore) refund bill for importers.

Supreme Court Blow to Trump’s IEEPA Tariffs

The 6-3 ruling on Feb 20 declared Trump's use of IEEPA for broad tariffs overstepped authority. CBP removed all related codes from its system. Yet, no clarity on refunds for tariffs collected in the last three days—or the massive past haul generating $500 million daily.

Trump fired back on Truth Social, calling the verdict "foolish" but claiming it boosted his powers under other laws. "If any country plays games, higher tariffs await," he warned.

Trump Rolls Out 15% Global Tariff Under Section 122

Hours after the ruling, Trump unveiled a uniform Trump 15% global tariff on all imports starting today, via Section 122 of the 1974 Trade Act. This allows quick 15% levies for 150 days in economic emergencies, needing Congress approval beyond that.

• Exemptions: Beef, tomatoes, oranges, critical minerals, medicines, electronics, passenger vehicles.
  
  

• Historical nod: Echoes Nixon's 10% tariff in 1971 amid dollar woes.
  
  

Sections 232 (national security, e.g., steel/aluminum) and 301 (unfair trade, e.g., China IP theft) remain intact.

India US Trade Impact: Uncertainty Looms

India US trade impact intensifies. Indian goods, previously at 26-50%, now face this 15% blanket. A temporary US-India deal could ease it, but Congress extension and future legal moves cloud the outlook.

Experts like trade analyst Rajiv Kumar note: "Short-term relief for high-tariff items, but exporters must diversify amid volatility." Actionable tip: Indian firms should audit Section 232 tariffs exposure and eye FTAs.

This US halts emergency tariffs saga underscores Trump's "America First" push, but risks retaliation. Watch for refunds, court challenges, and India talks—global supply chains hang in balance.

Indian Exports Get Major Boost from India-US Trade Deal

Indian exports are expected to witness an exponential rise following the India-US trade deal, after former US President Donald Trump claimed that tariffs on Indian goods have been slashed sharply. The move has been welcomed by top exporters and industry bodies, who believe the decision will bring immediate relief to labour-intensive sectors and strengthen India’s position in the US market.

According to exporters, the reduction of the so-called ‘Trump Tariffs’ from 50% to 18%, effective immediately, could be a game-changer for several key industries that were under pressure due to high duties and global slowdown.

US Remains India’s Largest Trading Partner

Highlighting the importance of the development, Confederation of Indian Industry (CII) President Rajiv Memani told ANI that the United States is not only the world’s largest economy but also India’s biggest trading partner.

 “Total Indian exports to the US are estimated at around $80–90 billion annually,” Memani said.

This strong trade relationship makes any tariff relief from the US especially significant for Indian exporters looking to expand volumes and improve competitiveness.

Labour-Intensive Sectors to Gain the Most

Breaking down the export numbers, Memani explained that nearly 50–60% of India’s exports to the US—roughly $50 billion—come from labour-intensive sectors such as:

 Textiles and garments

 Leather and footwear

 Fisheries

 Gems and jewellery

 Auto components

 Engineering goods

He added that the tariff relief opens up an export opportunity worth nearly $50 billion (around ₹4.50 lakh crore), particularly for sectors that have faced challenges in recent months.

Ratings Agencies and Industry Echo Optimism

Global ratings agency Moody’s also termed the tariff reduction credit-positive for Indian exports, especially for gems, jewellery, textiles and apparel—India’s top export segments.

Chandrima Chatterjee, Secretary General of the Confederation of Indian Textile Industry (CITI), called the finalisation of the India-US trade deal a “major relief” for the textile and apparel industry.

Legal and trade experts agree. Rudra Kumar Pandey, Partner at Shardul Amarchand Mangaldas & Co., told PTI that sectors such as textiles, gems and jewellery, leather, engineering goods and auto components will benefit disproportionately, as they directly compete with Vietnam and Bangladesh in the US market.

Meanwhile, Sanjay Agarwal, Managing Director of Century Plyboards India Ltd, noted that the new trade dynamics could also help pharma, engineering and auto ancillary sectors.

India’s GDP Outlook Improves

The positive sentiment has spilled over into economic forecasts. Global investment banks have raised India’s GDP growth projections following the tariff cut announcement. Goldman Sachs, according to ANI, revised its CY26 real GDP growth forecast upward by 20 basis points to 6.9% year-on-year.

Key Exemptions Still in Place

It is also noteworthy that sectors like pharmaceuticals and consumer electronics were already exempted from Trump Tariffs, further supporting Indian exports in high-value categories.

Why This Matters Now

At a time of global trade uncertainty, the India-US trade deal offers timely relief. With lower tariffs, Indian exporters are better placed to scale up shipments, protect jobs in labour-intensive sectors, and contribute to faster economic growth—making this development crucial for India’s export-led growth strategy.